Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in Severe Mast Cell Activation Syndrome (MCAS)
NCT05449444Phase 2Unknown
- Sponsor
- AB Science
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of masitinib in Mast Cell Activation Syndrome (MCAS) (3 arms), sponsored by AB Science. Primary endpoint: Confirmed response at 50% at 24 weeks. Status: unknown.
02
Drugs
masitinib
03
Conditions
Mast Cell Activation Syndrome (MCAS)
Beyond the preview
Go deeper on NCT05449444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449444.